• Latest
  • Trending
GRAIL (GRAL) Stock Jumps 22% Ahead of FDA Review of Galleri Cancer Test

GRAIL (GRAL) Stock Jumps 22% Ahead of FDA Review of Galleri Cancer Test

September 21, 2026
Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

November 17, 2026
Figment to Support Staking on BNY’s Custody Platform

Figment to Support Staking on BNY’s Custody Platform

November 17, 2026
AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

November 16, 2026
Trezor Customer Data Exposed in Third Partner Breach

Trezor Customer Data Exposed in Third Partner Breach

November 16, 2026
Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

November 16, 2026
TSMC (TSM) Stock Drops 6% as Nvidia CEO Exit Rattles Asian Chip Names

TSMC (TSM) Stock Drops 6% as Nvidia CEO Exit Rattles Asian Chip Names

November 16, 2026
7 Major Banks Reveal XRP ETF Holdings in Latest SEC Filings

7 Major Banks Reveal XRP ETF Holdings in Latest SEC Filings

November 16, 2026
Hong Kong Reaffirms Year-End Crypto Licensing Bill

Hong Kong Reaffirms Year-End Crypto Licensing Bill

November 16, 2026
Sandisk (SNDK) Stock Slides 5% Even After Beating Earnings Estimates – Here’s Why

Sandisk (SNDK) Stock Falls 6% Ahead of 8-for-1 Split as Memory Selloff Deepens

November 16, 2026
  • Privacy Policy
Tuesday, November 17, 2026
MtRushmoreCrypto - Where Crypto Rocks
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us
No Result
View All Result
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us
No Result
View All Result
Logo
No Result
View All Result
Home Crypto Technical Analysis

GRAIL (GRAL) Stock Jumps 22% Ahead of FDA Review of Galleri Cancer Test

J_News by J_News
September 21, 2026
in Crypto Technical Analysis, Top News
0
GRAIL (GRAL) Stock Jumps 22% Ahead of FDA Review of Galleri Cancer Test
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter


Follow on Google News

TLDR

  • GRAIL stock jumped more than 22% Monday as investors looked ahead to an FDA advisory committee meeting on Sept. 23.
  • The panel will review GRAIL’s premarket approval application for Galleri, its multi-cancer early detection blood test.
  • The FDA panel will discuss, vote and make recommendations, but its decision is non-binding.
  • Galleri is designed to detect cancer-specific methylation patterns in blood and screen adults aged 50 and older for multiple cancer types.
  • The stock remains risky because the panel outcome is uncertain and GRAIL is still deeply unprofitable.

GRAIL (GRAL) stock jumped more than 22% Monday as investors positioned ahead of a major regulatory event later this week. The move came despite no new company press release or SEC filing driving the rally.


GRAL Stock Card
GRAIL Inc., GRAL

The main catalyst is an FDA advisory committee meeting scheduled for Wednesday, Sept. 23. The Molecular and Clinical Genetics Panel will review GRAIL’s premarket approval application for its Galleri multi-cancer early detection blood test.

The meeting is scheduled to run from 9 a.m. to 6 p.m. ET and will be open to the public. The panel is expected to discuss the evidence, make recommendations and vote on the application.

Importantly, this is not yet a final FDA approval decision. Advisory committees provide independent recommendations, and the FDA generally considers those recommendations but is not legally required to follow them.

Galleri FDA Review Becomes the Main Catalyst

Galleri is a prescription-only blood test that uses next-generation sequencing to detect cancer-specific methylation patterns in cell-free DNA. GRAIL is seeking approval for screening adults aged 50 and older for the early detection of multiple types of cancer.

The test is also designed to predict where a detected cancer signal may have originated. Any positive signal would still need to be followed by further diagnostic testing from a healthcare professional.


Betpanda


The FDA meeting has been known since August, but interest is increasing as the review date approaches. GRAIL officially announced the Sept. 23 advisory committee meeting on Aug. 7.

Related articles

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

November 17, 2026
Figment to Support Staking on BNY’s Custody Platform

Figment to Support Staking on BNY’s Custody Platform

November 17, 2026

That makes Monday’s rally largely an anticipation trade. Investors appear to be positioning for a potentially favorable panel discussion or vote rather than reacting to a new regulatory decision.

Trading activity also increased sharply Monday. The move extended GRAL’s gains over the past year and pushed the stock well above levels seen earlier in 2026.

FDA Outcome Carries Major Risk

The upcoming panel meeting could be an important milestone for GRAIL, but the outcome remains uncertain. Advisory panels can raise questions about clinical evidence, test accuracy, patient selection and whether the benefits outweigh the risks.

Galleri also faces scrutiny over its clinical data. Reports have noted that a large randomized U.K. study failed to meet its primary endpoint, which could feature in the FDA panel’s discussion of the evidence supporting the test.

GRAIL remains financially dependent on successful commercialization of Galleri and broader insurance coverage. The company recently reported quarterly revenue of $44.69 million while continuing to post substantial losses.

That leaves the stock highly sensitive to regulatory headlines. A favorable panel recommendation could improve expectations for eventual approval, while concerns raised by the committee could trigger equally sharp downside.

Investors should also remember that even a positive advisory committee vote would not equal formal FDA approval. The agency would still need to complete its review and issue a final decision.

For Monday, the clearest catalyst is anticipation of Wednesday’s FDA advisory committee meeting. The panel will review and vote on Galleri’s application on Sept. 23, making it the key event currently driving GRAL trading.


Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.

Sign up today and get 50% OFF full access to our premium stock picks.

Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.



Source link

ShareTweetShareShare

Related Posts

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

Meta Has Staff Testing a Cashless Prediction Market App: WSJ

by J_News
November 17, 2026
0

Key TakeawaysMeta staff are testing Takes, a prediction app that uses points called “cred” instead of money, WSJ reported.Meta declined...

Figment to Support Staking on BNY’s Custody Platform

Figment to Support Staking on BNY’s Custody Platform

by J_News
November 17, 2026
0

TL;DR Figment will provide validator infrastructure for BNY's institutional staking offering. Eligible clients would access staking within the bank's digital...

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

AMD Stock Slips Premarket as Huang Exit Rattles Chip Sector

by J_News
November 16, 2026
0

TLDR AMD stock fell about 5% to $508.16 in Monday premarket trading after a 9% drop on Friday. The stock...

Trezor Customer Data Exposed in Third Partner Breach

Trezor Customer Data Exposed in Third Partner Breach

by J_News
November 16, 2026
0

Hardware wallet maker Trezor has disclosed its third partner data breach this year, warning that an attacker accessed personal information...

Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

Shiba Inu (SHIB) Bearish Rally is Fading, Solana (SOL) Death Cross Isn’t Dangerous, Stellar (XLM) Recovery Signal Potential: Crypto Market Review

by J_News
November 16, 2026
0

The crypto market remains under pressure, with Bitcoin dropping to a four-month low around $62,000 on November 15. SHIB, SOL...

Load More

Enter your email address:

Delivered by FeedBurner

Quick Navigate

  • Home
  • Crypto
  • Crypto Technical Analysis
  • Top News
  • Thank You
  • Store
  • About Us

Top News

Gram Price: Jumps 9% as Telegram Opens Money Wallet to More Users

Best Perp DEXes in 2026: Hyperliquid, Aster, Lighter, edgeX, and ApeX Omni Compared

Why Does Ethereum Gas Estimation Fail?

© 2021 mtrushmorecrypto - Crypto Related News Blog

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
No Result
View All Result
  • Home
  • Top News
  • Crypto
  • Crypto Technical Analysis
  • About Us

© 2021 mtrushmorecrypto - Crypto Related News Blog